A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Duration of Treatment
Baseline up to Day 28 after last dose of study treatment
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A6181030
NCT00798889
March 2004
December 2011
Name | Location |
---|---|
Pfizer Investigational Site | Birmingham, Alabama 35205 |
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Rochester, Minnesota 55905 |
Pfizer Investigational Site | Cincinnait, Ohio 45236 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Aurora, Colorado 80012 |
Pfizer Investigational Site | Carmel, Indiana 46032 |
Pfizer Investigational Site | North Adams, Massachusetts 01247 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Santa Fe, New Mexico 87505 |
Pfizer Investigational Site | Asheville, North Carolina 28801 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
Pfizer Investigational Site | Easley,, South Carolina 29640 |
Pfizer Investigational Site | Milwaukee, Wisconsin 53215 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |